Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820797 | 0.79 | KDM4E (0.53) | BACE1TYRNLRP3KDM4EALDH1A1 | |
| SCHEMBL4137554 | 0.79 | PDE3B (0.47) | BACE1NLRP3HDAC1ALOX5OR51E2 | |
| Letestuianin C SCHEMBL4410123 | 0.78 | F2RL1 (0.60) | BACE1HDAC8ALOX5OR51E2KDM4E | |
| SCHEMBL29411451 | 0.78 | HDAC1 (0.57) | BACE1TYRNLRP3HDAC1HDAC8 | |
| SCHEMBL21045111 | 0.78 | HDAC1 (0.57) | BACE1TYRNLRP3HDAC1HDAC8 | |
| SCHEMBL21274689 | 0.78 | BACE1 (0.50) | BACE1TYRNLRP3HDAC1HDAC8 | |
| SCHEMBL11976581 | 0.77 | ABL1 (0.46) | BACE1NLRP3HDAC1HDAC8KDM4E | |
| SCHEMBL12601802 | 0.74 | IAPP (0.65) | TYRALOX5OR51E2KDM4EALDH1A1 | |
| SCHEMBL18132167 | 0.74 | CYP1A2 (0.58) | BACE1TYRNLRP3HDAC1HDAC8 | |
| SCHEMBL3217413 | 0.73 | BACE1 (0.53) | BACE1HDAC8ALOX5OR51E2HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885TYR 3484/4885NLRP3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.